Aptamer Group Share News (APTA)

Aptamer Group Information

Share Price Information for Aptamer Group (APTA)

Share Price is delayed by 15 minutes

Get Live Data

0.525 0.025 (4.76%)

Bid:

0.50

Ask:

0.55

Spread: 0.05 (10.00%)

Market Cap: £19.00m

Last checked at -

Intraday Aptamer Group Share Chart

REMOVE ADS

Aptamer and Neuro-Bio begin Alzheimer's test development second phase

Thu, 22nd Feb 2024 13:21

(Alliance News) - Aptamer Group PLC on Thursday said it has entered the second phase of developing Optimer binders for the early diagnosis of Alzheimer's disease alongside Neuro-Bio Ltd.

Shares in Aptamer were up 14% to 0.72 pence each in London on Thursday afternoon.

York, England-based biotechnology firm Aptamer said this was part of its ongoing partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease.

Aptamer said this latest phase involves development of an additional Optimer binder against the innovative Neuro-Bio target implicated in Alzheimer's disease, with the goal of developing reagents for a lateral flow test for early disease detection.

Following the earlier identification of Optimer binders to this novel Alzheimer's disease biomarker, Aptamer said these binders have been "characterised for use in lateral flow and biosensor assays".

"Common lateral flow test formats require a pair of binders to increase diagnostic test accuracy. To prevent the need for animal-derived antibodies in its Alzheimer's disease diagnostic, Neuro-Bio now requires the development of additional binders to support the lateral flow test format and deliver a wholly Optimer-powered test," the company explained.

"As Optimer binders are oligonucleotide-based, rather than protein-based like antibodies, they offer further advantages including scalability of manufacture, improved shelf-life and tuneability benefits that will allow more stable and specific reagents for use in lateral flow tests."

Apatamer Chair Steve Hull commented: "We are very pleased to continue our exciting relationship with Neuro-Bio to deliver the specific Optimer binders needed to enable this revolutionary diagnostic for this devastating disease. It is great to work with such enthusiastic partners that understand our Optimer technology's benefits and are actively seeking solutions to overcome the industry's problems with antibodies."

Neuro-Bio Chief Executive Officer Susan Greenfield added: "The first phase proved productive and very promising. Now, this next stage takes us closer to realising a highly novel and much needed technology for detecting neurodegenerative diseases at a very early stage."

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com